Literature DB >> 25712380

Maternal Phenylketonuria: Long-term Outcomes in Offspring and Post-pregnancy Maternal Characteristics.

S E Waisbren1, F Rohr, V Anastasoaie, M Brown, D Harris, A Ozonoff, S Petrides, A Wessel, H L Levy.   

Abstract

Maternal phenylketonuria (MPKU) is a well-recognized complication of PKU and one of the most potent teratogenic syndromes of pregnancy. Virtually all offspring from untreated pregnancies in women with classic PKU have intellectual disabilities and microcephaly. Congenital heart disease and intrauterine growth retardation occur many times more often than expected in the general population. Control of maternal blood phenylalanine during pregnancy prevents most if not all of these complications. Previous studies demonstrated the benefits of treatment in terms of birth parameters and early development. In this study, physical examinations, a medical history, and neuropsychological evaluation were obtained in 47 children from 24 mothers with PKU who received treatment during pregnancy. Mothers were interviewed and administered an abbreviated IQ test. Associations between maternal factors and offspring outcomes were also analyzed.The 21 male and 26 female offspring ranged in age from 1 month to 26 years with 21 (62%) over 6 years. Results indicated mean intercanthal distances above the 70th percentile. Microcephaly was present in 19% of offspring, with head circumference below the third percentile. None of the offspring had cardiac anomalies. Mean offspring IQ was 94 ± 19, with 12% performing in the range of intellectual disability (IQ < 70). Among children >5 years of age, 25% had learning disabilities, 31% had attention deficit hyperactivity disorder (ADHD), 22% were on ADHD medication, and 34% had a diagnosis of anxiety and/or depression. Among the 24 mothers, 12 reported following the diet for PKU. Only one woman on diet had a blood phenylalanine concentration <360 μmol/L (recommended range) and the majority had indications of poor nutritional status. Mean maternal Full Scale IQ was 94 ± 16 (range = 61-117), with 25% performing in the borderline intellectual range (IQ < 85). Verbal IQ was significantly lower than Performance IQ (p = 0.01, CI 2.7, 16.1). On the self-report Beck Depression Inventory, Second Edition, 25% received scores indicating mild to moderate depression, and on the Beck Anxiety Inventory, 46% reported mild to moderate anxiety. Offspring IQ correlated with maternal metabolic control during pregnancy (r = 0.51), maternal IQ (r = -0.62), and socioeconomic position (r = -0.48). Offspring with ADHD, learning disabilities, or emotional disturbances were more likely to have mothers with anxiety and/or depression. To ensure optimal offspring outcomes, healthcare providers need to assess maternal nutrition, blood phenylalanine concentrations, cognitive abilities, and socioeconomic position. Interventions can then be initiated that reduce psychosocial stressors and enhance adherence to diet and positive parenting, which in turn can lead to better cognitive functioning, behavior, and emotional well-being in their children.

Entities:  

Year:  2015        PMID: 25712380      PMCID: PMC4470942          DOI: 10.1007/8904_2014_365

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  30 in total

1.  Behavior rating inventory of executive function.

Authors:  Ida Sue Baron
Journal:  Child Neuropsychol       Date:  2000-09       Impact factor: 2.500

2.  Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication.

Authors:  Ronald C Kessler; Wai Tat Chiu; Olga Demler; Kathleen R Merikangas; Ellen E Walters
Journal:  Arch Gen Psychiatry       Date:  2005-06

Review 3.  Anxiety and anxiety disorders in children and adolescents: developmental issues and implications for DSM-V.

Authors:  Katja Beesdo; Susanne Knappe; Daniel S Pine
Journal:  Psychiatr Clin North Am       Date:  2009-09

4.  Psychiatric symptoms and disorders in phenylketonuria.

Authors:  V L Brumm; D Bilder; S E Waisbren
Journal:  Mol Genet Metab       Date:  2010       Impact factor: 4.797

5.  Psychosocial issues and outcomes in maternal PKU.

Authors:  Richard Koch; Friedrich Trefz; Susan Waisbren
Journal:  Mol Genet Metab       Date:  2010       Impact factor: 4.797

6.  Impact of the phenylalanine hydroxylase gene on maternal phenylketonuria outcome.

Authors:  Flemming Güttler; Colleen Azen; Per Guldberg; Anne Romstad; William B Hanley; Harvey L Levy; Reuben Matalon; Bobbye M Rouse; Friedrich Trefz; Felix de la Cruz; Richard Koch
Journal:  Pediatrics       Date:  2003-12       Impact factor: 7.124

7.  Cognitive and behavioral development in maternal phenylketonuria offspring.

Authors:  Susan E Waisbren; Colleen Azen
Journal:  Pediatrics       Date:  2003-12       Impact factor: 7.124

Review 8.  The impact of vitamin D in pregnancy on extraskeletal health in children: a systematic review.

Authors:  Henrik T Christesen; Claes Elvander; Ronald F Lamont; Jan S Jørgensen
Journal:  Acta Obstet Gynecol Scand       Date:  2012-12       Impact factor: 3.636

9.  Agoraphobia in phenylketonuria.

Authors:  S E Waisbren; H L Levy
Journal:  J Inherit Metab Dis       Date:  1991       Impact factor: 4.982

10.  Psychiatric morbidity and social functioning among adults with borderline intelligence living in private households.

Authors:  A Hassiotis; A Strydom; I Hall; A Ali; G Lawrence-Smith; H Meltzer; J Head; P Bebbington
Journal:  J Intellect Disabil Res       Date:  2008-02
View more
  5 in total

Review 1.  Amino acid disorders.

Authors:  Ermal Aliu; Shibani Kanungo; Georgianne L Arnold
Journal:  Ann Transl Med       Date:  2018-12

2.  Assessing Psychological Functioning in Metabolic Disorders: Validation of the Adaptive Behavior Assessment System, Second Edition (ABAS-II), and the Behavior Rating Inventory of Executive Function (BRIEF) for Identification of Individuals at Risk.

Authors:  Susan E Waisbren; Jianping He; Robert McCarter
Journal:  JIMD Rep       Date:  2015-02-25

Review 3.  Genetic etiology and clinical challenges of phenylketonuria.

Authors:  Nasser A Elhawary; Imad A AlJahdali; Iman S Abumansour; Ezzeldin N Elhawary; Nagwa Gaboon; Mohammed Dandini; Abdulelah Madkhali; Wafaa Alosaimi; Abdulmajeed Alzahrani; Fawzia Aljohani; Ehab M Melibary; Osama A Kensara
Journal:  Hum Genomics       Date:  2022-07-19       Impact factor: 6.481

4.  Inhibiting neutral amino acid transport for the treatment of phenylketonuria.

Authors:  Adam M Belanger; Malgorzata Przybylska; Estelle Gefteas; Matthew Furgerson; Sarah Geller; Alla Kloss; Seng H Cheng; Yunxiang Zhu; Nelson S Yew
Journal:  JCI Insight       Date:  2018-07-26

5.  Ten years of specialized adult care for phenylketonuria - a single-centre experience.

Authors:  Ulrike Mütze; Alena Gerlinde Thiele; Christoph Baerwald; Uta Ceglarek; Wieland Kiess; Skadi Beblo
Journal:  Orphanet J Rare Dis       Date:  2016-03-24       Impact factor: 4.123

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.